The above studies indicate that KRT17, TWEAK, PCSK9, and ANGPTL4 have the potential to serve as therapeutic targets for psoriasis and tumors and require the development of nucleic acid drugs, biologics, and small-molecule drugs against them. This evidence concerns the gene TNFSF12 and psoriasis.